Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study involves cognitive behavioral therapy (CBT) and a medication called D-cycloserine
(DCS), which is thought to help reduce panic symptoms more effectively by interacting with
N-methyl-D-aspartate (NMDA) glutamate receptors, facilitating many forms of learning
including the extinction of fear. Participants will be randomly assigned (like flipping a
coin) to receive either DCS or a placebo in addition to CBT.